SIRT1 and Friedreich ataxia: For Fanconi anemia (FA), a congenital disorder characterized by bone marrow failure, FA-iPSCs were used for drug screening of several compounds known to improve FA phenotypes, such as resveratrol (Sirt1 activator), danazol (synthetic androgen), and doramapimod (p38 MAPK inhibitor), based on the evaluation of the effects on hematopoietic differentiation.